Literature DB >> 11741812

Altered hemodynamics controls matrix metalloproteinase activity and tenascin-C expression in neonatal pig lung.

Peter Lloyd Jones1, Rene Chapados, H Scott Baldwin, Gary W Raff, Eugene V Vitvitsky, Thomas L Spray, J William Gaynor.   

Abstract

Tenascin-C (TN-C) expression and matrix metalloproteinase (MMP) activity are induced within remodeling pulmonary arteries (PAs), where they promote cell growth. Because pulmonary vascular disease in children with congenital heart defects is commonly associated with changes in pulmonary hemodynamics, we hypothesized that changes in pulmonary blood flow regulate TN-C and MMPs. To test this, we ligated the left PAs of neonatal pigs. After 12 wk, we evaluated the levels of TN-C and MMPs in control and ligated lung tissue. Modifying pulmonary hemodynamics increased TN-C mRNA and protein expression, MMP activity, and the DNA-binding activity of Egr-1, a transcription factor that has been shown to activate TN-C expression. To link MMP-mediated remodeling of the extracellular matrix to increased TN-C expression and Egr-1 activity, porcine PA smooth muscle cells were cultivated either on denatured type I collagen, which supported TN-C expression and Egr-1 activity, or on native collagen, which had the opposite effect. These data provide a framework for understanding how changes in pulmonary blood flow in the neonate modify the tissue microenvironment and cell behavior.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11741812     DOI: 10.1152/ajplung.00171.2001

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  7 in total

1.  Blood flow dynamics of one cardiac cycle and relationship to mechanotransduction and trabeculation during heart looping.

Authors:  Barbara Garita; Michael W Jenkins; Mingda Han; Chao Zhou; Michael Vanauker; Andrew M Rollins; Michiko Watanabe; J G Fujimoto; Kersti K Linask
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-14       Impact factor: 4.733

2.  Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertension.

Authors:  D Dunbar Ivy; Ivan F McMurtry; Kelley Colvin; Masatoshi Imamura; Masahiko Oka; Dong-Seok Lee; Sarah Gebb; Peter Lloyd Jones
Journal:  Circulation       Date:  2005-05-31       Impact factor: 29.690

3.  Quantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function.

Authors:  Agne Taraseviciute; Benjamin T Vincent; Pepper Schedin; Peter Lloyd Jones
Journal:  Am J Pathol       Date:  2009-12-30       Impact factor: 4.307

Review 4.  Advances in tenascin-C biology.

Authors:  Kim S Midwood; Thomas Hussenet; Benoit Langlois; Gertraud Orend
Journal:  Cell Mol Life Sci       Date:  2011-08-05       Impact factor: 9.261

5.  Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention.

Authors:  Doris M Benbrook; Stan Lightfoot; James Ranger-Moore; Tongzu Liu; Shylet Chengedza; William L Berry; Igor Dozmorov
Journal:  Gene Regul Syst Bio       Date:  2008

6.  Cardiopulmonary dysfunction in the Osteogenesis imperfecta mouse model Aga2 and human patients are caused by bone-independent mechanisms.

Authors:  Frank Thiele; Christian M Cohrs; Armando Flor; Thomas S Lisse; Gerhard K H Przemeck; Marion Horsch; Anja Schrewe; Valerie Gailus-Durner; Boris Ivandic; Hugo A Katus; Wolfgang Wurst; Catherine Reisenberg; Hollis Chaney; Helmut Fuchs; Wolfgang Hans; Johannes Beckers; Joan C Marini; Martin Hrabé de Angelis
Journal:  Hum Mol Genet       Date:  2012-05-15       Impact factor: 6.150

7.  FAK induces expression of Prx1 to promote tenascin-C-dependent fibroblast migration.

Authors:  David M McKean; Lila Sisbarro; Dusko Ilic; Nihal Kaplan-Alburquerque; Raphael Nemenoff; Mary Weiser-Evans; Michael J Kern; Peter Lloyd Jones
Journal:  J Cell Biol       Date:  2003-04-28       Impact factor: 10.539

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.